US Stock MarketDetailed Quotes

CLNN Clene

Watchlist

0.3801
+0.0065+1.74%

Close Jun 18 16:00 ET

0.3900
+0.0099+2.60%

Post 19:28 ET

48.82MMarket Cap-927P/E (TTM)

Clene Stock Forum

Mafiosa818

10 hours ago

$Clene(CLNN.US)$ 👀

Trytosaveabit

14 hours ago

Update

$Clene(CLNN.US)$ Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting 2 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE - Survival analyses with CNM-Au8 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline (hazard ratio: 0.431, p=0.0002) Average of 28% NfL reduction observed in an NfL respon...

$Clene(CLNN.US)$ 😌😌😌

$Clene(CLNN.US)$ ok no wonder it's on ssr

Anthony tan81

May 29 13:58

$Clene(CLNN.US)$ pop
👀👀👀
@Trytosaveabit

Trytosaveabit

May 28 06:33

Update

$Clene(CLNN.US)$ Clene Provides Update on Its Nih-Funded Expanded Access Program for Cnm-AU8® in ALS (Act-Eap) First Patient, First Visit Is Planned for Early June 2024

steven smith38

Apr 17 19:30

$Clene(CLNN.US)$ its so wired. how a company is doing great no law suits. no lay off. no debts in rear. but all out of nowhere it just drop. something is very fisher. about stocks. . like what is the answer. and a company get great new contracts. Anyone in the world have a answer????????? we would like to no

Trytosaveabit

Apr 17 18:37

Hmm?

$Clene(CLNN.US)$ With the poster presentation news and NDA approaching? Just may be time to start scaling in here? NFA just thinking outloud

Trytosaveabit

Apr 17 15:15

Wish I had faith in analysts! Hehehe

$Clene(CLNN.US)$ The Analyst Verdict: Clene In The Eyes Of 5 Experts
Benzinga· 7 mins ago

Stock Region

Apr 17 13:21

Multiple Sclerosis Treatment Shows Promising Results Unveiled By Medical Company

Breakthrough in Multiple Sclerosis Treatment: Clene’s CNM-Au8® Shows Promising Results.
In a significant development for the multiple sclerosis (MS) community, Clene Inc. recently unveiled the results of its Phase 2 VISIONARY-MS long-term extension study at the prestigious 2024 American Academy of Neurology (AAN) Annual Meeting. The findings are nothing short of groundbreaking, demonstrating substantial evidence that...

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall